TORONTO, Nov. 30, 2017 /PRNewswire/ — Thornhill and Rostrum celebrate the finalization of a Technology Development Agreement which includes the licensing of certain Thornhill IP and an investment by Rostrum into Thornhill. This agreement is aimed to further Rostrum’s development of its Pulmonary Health Monitoring during ventilation, in ICU, OR and ER applications while supporting Thornhill’s commercialization efforts of their own innovative products.
“We are both extremely excited and motivated with this development that will support both companies’ mission to providing effective solutions to critical care,” Kipton Lade and Awni Ayoubi (Presidents/CEOs for Thornhill and Rostrum) said.
“This Technology Development Agreement is a great example of the important role intellectual property plays in ensuring a healthy and vibrant medical technology ecosystem in Canada.” – Kipton Lade, President & CEO, Thornhill Research.
About Thornhill Research Inc.
Thornhill Research, doing business as Thornhill Medical, makes innovative healthcare devices. Our founder, Dr. Joseph Fisher, is a world-renowned research scientist in the field of anesthesiology and cardiovascular intensive care. Since spinning off from the University Health Network in 2003, Thornhill Research has built upon his expertise to develop and manufacture compact mobile emergency respiration and anesthesia devices. Our full story can be found on our website www.thornhillmedical.com.
About Rostrum Medical Innovations
Rostrum Medical is a privately held corporation, registered under the laws of Canada. Rostrum Medical commenced its operation in January 2009, with a focus on providing medical practitioners with innovative and useful solutions to everyday challenges experienced in the healthcare industry. A team of leading clinicians, combined with engineering and business expertise, allows Rostrum Medical to deliver leading-edge solutions to problematic uncertainties in modern day practice.
Thornhill Research Inc.
SOURCE Thornhill Research Inc.